Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals's GHG Emissions Data Preview
In 2024, Alnylam Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Alnylam Pharmaceuticals has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Alnylam Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alnylam Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Alnylam Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals amounted to 13,509 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals increased by 0.48%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
Alnylam Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Alnylam Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Alnylam Pharmaceuticals were 3,832 metric tons of CO₂ equivalent (tCO₂e). a
Has Alnylam Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 1 emissions have increased by 25.47%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2023), Alnylam Pharmaceuticals's Scope 1 emissions increased by 8.07%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Alnylam Pharmaceuticals's Scope 2 emissions?
In 2024, Alnylam Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 8,018 tCO₂e using the market-based method and 9,677 tCO₂e using the location-based method. a
Has Alnylam Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions ( Location-Based) have increased by 13.61%, reflecting a rising long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2023), Alnylam Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Alnylam Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does Alnylam Pharmaceuticals use for Scope 2 reporting?
In 2024, Alnylam Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method. a
Alnylam Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Alnylam Pharmaceuticals's Value Chain Emissions
In 2024, Alnylam Pharmaceuticals reported 160,413 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of Alnylam Pharmaceuticals includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Alnylam Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Alnylam Pharmaceuticals's Scope 3 emissions?
In 2024, Alnylam Pharmaceuticals reported total Scope 3 emissions of 160,413 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Alnylam Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2020, Alnylam Pharmaceuticals's Scope 3 emissions have increased by 5,135.41%, reflecting a rising long-term trend in Scope 3 emissions over time. a b
Compared to the previous year (2023), Alnylam Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Alnylam Pharmaceuticals 's emissions have plateaued with no significant change in its value chain footprint. a
What categories of Scope 3 emissions does Alnylam Pharmaceuticals disclose?
In 2024, Alnylam Pharmaceuticals reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Alnylam Pharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to Alnylam Pharmaceuticals's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 138,154 tCO₂e (86.12%)
- Capital Goods (Cat. 2): 6,755 tCO₂e (4.21%)
- Business Travel (Cat. 6): 5,139 tCO₂e (3.2%)
Alnylam Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Alnylam Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Alnylam Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 3,832 tCO₂e and total revenues of USD 2,248 millions. This translates into an emissions intensity of 1.7 tCO₂e per millions USD. a
Alnylam Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Alnylam Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Alnylam Pharmaceuticals reported a Scope 1 emissions intensity of 1.7 tCO₂e per millions USD. Compared to the peer group median of 2.35 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does Alnylam Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Alnylam Pharmaceuticals ranked 10 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Alnylam Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Alnylam Pharmaceuticals's Total Carbon Footprint
In 2024, Alnylam Pharmaceuticals reported a total carbon footprint of 173,922 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.52% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. a
The largest contributor to Alnylam Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 92.23% of the company's total carbon footprint, followed by Scope 2 emissions at 5.56%. a